Phuturdex › Diseases › Endocrine system disease
Drugs in development · updated 30 October 2026
Endocrine system disease: drugs in development
As of 30 October 2026 there are 18 active clinical trials (recruiting or ongoing, phases I–III) on 19 drugs for endocrine system disease. 9 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PF-08653944 | III | 2 | NCT07595549 |
| Retatrutide | III | 2 | NCT06260722 |
| Linsitinib | II–III | 1 | NCT06112340 |
| AMX0035 | II | 1 | NCT07699380 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT04807166 |
| APHD-012 | II | 1 | NCT05385978 |
| APHD-012P | II | 1 | NCT05385978 |
| BHV-1300 | I | 1 | NCT06980649 |
| ETHY-001 | I | 1 | NCT07885605 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| FinasteridePropecia®, Proscar® | II–III | 1 | NCT07742553 |
| OrforglipronFoundayo® | III | 1 | NCT07613307 |
| SemaglutideWegovy, Rybelsus | III | 1 | NCT06260722 |
| Testosterone cypionateAzmiro® | II–III | 1 | NCT07742553 |
| SelpercatinibLOXO-292, Retevmo® | I–II | 2 | NCT03157128 |
| TirzepatideZepbound, Mounjaro | II | 2 | NCT06820281 |
| CarboplatinCarboplatine, Paraplatin | II | 1 | NCT04807166 |
| PaclitaxelTaxol, Paxlitaxel | II | 1 | NCT04807166 |
| RepotrectinibAugtyro® | I–II | 1 | NCT03093116 |
| Testosterone EnanthateXyosted (Autoinjector)®, Delatestryl® | II | 1 | NCT04460872 |
Sorted by most advanced phase and number of active trials.
All 19 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Ovarian neoplasm 411 drugs
- Pancreatic neoplasm 395 drugs
- Type 2 diabetes 171 drugs
- Colorectal neoplasm 534 drugs
- Non-small-cell lung carcinoma 726 drugs
- Fallopian tube neoplasm 124 drugs
- Endometrial neoplasm 298 drugs
- Breast neoplasm 593 drugs
- Type-1 diabetes 80 drugs
- Stomach neoplasm 340 drugs
- Metastasis 493 drugs
- Diabetes 91 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Digestive System Diseases 36 drugs
- Urogenital Diseases 16 drugs
- Glandular and epithelial neoplasm 12 drugs
- Colorectal neoplasm 534 drugs
- Immune System Diseases 54 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D004700 “Endocrine System Diseases”.